GoodRx Holdings, Inc. reported a revenue of $202.97 million for the first quarter of 2025, marking a 3% increase from $197.88 million in the same period of 2024. The company achieved a net income of $11.05 million, a significant turnaround from a net loss of $1.01 million in the prior year. This resulted in a net income margin of 5.4%, compared to a net loss margin of 0.5% in the previous year. The increase in revenue was primarily driven by a 2% rise in prescription transactions revenue, which reached $148.92 million, despite a 4% decline in Monthly Active Consumers.
In terms of operational metrics, GoodRx reported a decrease in Monthly Active Consumers, which fell to 6.4 million from 6.7 million year-over-year. The decline was attributed to broader changes in the retail pharmacy landscape, including store closures and shifts in retail reimbursement models. The company also noted a decrease in subscription revenue, which fell by 7% to $21.02 million, largely due to the sunset of its Kroger Savings program. However, revenue from pharma manufacturer solutions increased by 17% to $28.65 million, reflecting ongoing growth in this segment.
GoodRx made a strategic acquisition in January 2025, purchasing the assets of VCRx for $30 million. This acquisition is expected to enhance the company's consumer reach and strengthen its prescription transactions offering. The company also reported a significant reduction in general and administrative expenses, which decreased by 28% year-over-year, primarily due to a legal settlement recognized in the first quarter of 2024. Additionally, the company recorded an impairment loss of $4.4 million related to a leased office space.
As of March 31, 2025, GoodRx had cash and cash equivalents totaling $300.98 million, down from $448.35 million at the end of 2024. The company’s total liabilities decreased to $640.92 million from $663.41 million, while stockholders' equity fell to $654.35 million from $724.66 million. GoodRx continues to maintain a strong liquidity position, with $91.7 million available under its revolving credit facility. Looking ahead, the company anticipates that ongoing changes in the retail pharmacy landscape may impact prescription volume and revenue, but expects these effects to be largely transient as consumers migrate to other pharmacies.
About GoodRx Holdings, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.